
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE53244C8AF11A3305244C004F501002.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="npjprecisoncol">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373877/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="NPJ Precision Oncology">
<meta name="citation_title" content="Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer">
<meta name="citation_author" content="Daniel A Ruiz-Torres">
<meta name="citation_author_institution" content="Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA">
<meta name="citation_author_institution" content="Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Broad Institute of MIT and Harvard, Cambridge, MA USA">
<meta name="citation_author" content="Ross D Merkin">
<meta name="citation_author_institution" content="Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Michael E Bryan">
<meta name="citation_author_institution" content="Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA">
<meta name="citation_author_institution" content="Broad Institute of MIT and Harvard, Cambridge, MA USA">
<meta name="citation_author" content="Julia Mendel">
<meta name="citation_author_institution" content="Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA">
<meta name="citation_author" content="Vasileios Efthymiou">
<meta name="citation_author_institution" content="Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA">
<meta name="citation_author" content="Thomas Roberts">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Manisha J Patel">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Jong C Park">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Amber Chevalier">
<meta name="citation_author_institution" content="NeoGenomics, Inc., Fort Meyers, FL USA">
<meta name="citation_author" content="Clodagh Murray">
<meta name="citation_author_institution" content="NeoGenomics, Inc., Fort Meyers, FL USA">
<meta name="citation_author" content="Lisa Gates">
<meta name="citation_author_institution" content="NeoGenomics, Inc., Fort Meyers, FL USA">
<meta name="citation_author" content="Christodoulos Pipinikas">
<meta name="citation_author_institution" content="NeoGenomics, Inc., Fort Meyers, FL USA">
<meta name="citation_author" content="Shannon L Stott">
<meta name="citation_author_institution" content="Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Broad Institute of MIT and Harvard, Cambridge, MA USA">
<meta name="citation_author_institution" content="Center for Engineering in Medicine &amp; Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA">
<meta name="citation_author" content="Adam S Fisch">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Department of Pathology, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Lori J Wirth">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_author" content="Daniel L Faden">
<meta name="citation_author_institution" content="Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA">
<meta name="citation_author_institution" content="Department of Medicine, Harvard Medical School, Boston, MA USA">
<meta name="citation_author_institution" content="Broad Institute of MIT and Harvard, Cambridge, MA USA">
<meta name="citation_author_institution" content="Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA">
<meta name="citation_publication_date" content="2025 Aug 22">
<meta name="citation_volume" content="9">
<meta name="citation_firstpage" content="298">
<meta name="citation_doi" content="10.1038/s41698-025-01084-4">
<meta name="citation_pmid" content="40846896">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373877/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373877/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373877/pdf/41698_2025_Article_1084.pdf">
<meta name="description" content="Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive disease with limited predictive biomarkers, often leading to ineffective treatments and unnecessary toxicity. Circulating tumor DNA (ctDNA) provides a promising ...">
<meta name="og:title" content="Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive disease with limited predictive biomarkers, often leading to ineffective treatments and unnecessary toxicity. Circulating tumor DNA (ctDNA) provides a promising ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373877/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Searchâ€¦
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12373877">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41698-025-01084-4"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41698_2025_Article_1084.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12373877%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12373877/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12373877/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373877/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-npjprecisoncol.jpg" alt="NPJ Precision Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to NPJ Precision Oncology" title="Link to NPJ Precision Oncology" shape="default" href="https://www.nature.com/npjprecisiononcology/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">NPJ Precis Oncol</button></div>. 2025 Aug 22;9:298. doi: <a href="https://doi.org/10.1038/s41698-025-01084-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41698-025-01084-4</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22NPJ%20Precis%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22NPJ%20Precis%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22NPJ%20Precis%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22NPJ%20Precis%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruiz-Torres%20DA%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Daniel A Ruiz-Torres</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Daniel A Ruiz-Torres</span></h3>
<div class="p">
<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA </div>
<div class="p">
<sup>2</sup>Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>4</sup>Broad Institute of MIT and Harvard, Cambridge, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruiz-Torres%20DA%22%5BAuthor%5D" class="usa-link"><span class="name western">Daniel A Ruiz-Torres</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>4,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Merkin%20RD%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Ross D Merkin</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Ross D Merkin</span></h3>
<div class="p">
<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA </div>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>5</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Merkin%20RD%22%5BAuthor%5D" class="usa-link"><span class="name western">Ross D Merkin</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>5,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bryan%20ME%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Michael E Bryan</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Michael E Bryan</span></h3>
<div class="p">
<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA </div>
<div class="p">
<sup>4</sup>Broad Institute of MIT and Harvard, Cambridge, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bryan%20ME%22%5BAuthor%5D" class="usa-link"><span class="name western">Michael E Bryan</span></a>
</div>
</div>
<sup>1,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mendel%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Julia Mendel</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Julia Mendel</span></h3>
<div class="p">
<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mendel%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Julia Mendel</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Efthymiou%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Vasileios Efthymiou</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Vasileios Efthymiou</span></h3>
<div class="p">
<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Efthymiou%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Vasileios Efthymiou</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Roberts%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Thomas Roberts</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Thomas Roberts</span></h3>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>5</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Roberts%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Thomas Roberts</span></a>
</div>
</div>
<sup>3,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20MJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Manisha J Patel</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Manisha J Patel</span></h3>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>5</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20MJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Manisha J Patel</span></a>
</div>
</div>
<sup>3,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Park%20JC%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jong C Park</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jong C Park</span></h3>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>5</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Park%20JC%22%5BAuthor%5D" class="usa-link"><span class="name western">Jong C Park</span></a>
</div>
</div>
<sup>3,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chevalier%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Amber Chevalier</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Amber Chevalier</span></h3>
<div class="p">
<sup>6</sup>NeoGenomics, Inc., Fort Meyers, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chevalier%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Amber Chevalier</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murray%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Clodagh Murray</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Clodagh Murray</span></h3>
<div class="p">
<sup>6</sup>NeoGenomics, Inc., Fort Meyers, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murray%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Clodagh Murray</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gates%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Lisa Gates</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Lisa Gates</span></h3>
<div class="p">
<sup>6</sup>NeoGenomics, Inc., Fort Meyers, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gates%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lisa Gates</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pipinikas%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Christodoulos Pipinikas</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Christodoulos Pipinikas</span></h3>
<div class="p">
<sup>6</sup>NeoGenomics, Inc., Fort Meyers, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pipinikas%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Christodoulos Pipinikas</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stott%20SL%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Shannon L Stott</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Shannon L Stott</span></h3>
<div class="p">
<sup>2</sup>Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>4</sup>Broad Institute of MIT and Harvard, Cambridge, MA USA </div>
<div class="p">
<sup>7</sup>Center for Engineering in Medicine &amp; Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stott%20SL%22%5BAuthor%5D" class="usa-link"><span class="name western">Shannon L Stott</span></a>
</div>
</div>
<sup>2,</sup><sup>3,</sup><sup>4,</sup><sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fisch%20AS%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Adam S Fisch</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Adam S Fisch</span></h3>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>8</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fisch%20AS%22%5BAuthor%5D" class="usa-link"><span class="name western">Adam S Fisch</span></a>
</div>
</div>
<sup>3,</sup><sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wirth%20LJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Lori J Wirth</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Lori J Wirth</span></h3>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>5</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wirth%20LJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Lori J Wirth</span></a>
</div>
</div>
<sup>3,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faden%20DL%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Daniel L Faden</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Daniel L Faden</span></h3>
<div class="p">
<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA </div>
<div class="p">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div class="p">
<sup>4</sup>Broad Institute of MIT and Harvard, Cambridge, MA USA </div>
<div class="p">
<sup>5</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faden%20DL%22%5BAuthor%5D" class="usa-link"><span class="name western">Daniel L Faden</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>4,</sup><sup>5,</sup><sup>âœ‰</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA USA </div>
<div id="Aff2">
<sup>2</sup>Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA USA </div>
<div id="Aff3">
<sup>3</sup>Department of Medicine, Harvard Medical School, Boston, MA USA </div>
<div id="Aff4">
<sup>4</sup>Broad Institute of MIT and Harvard, Cambridge, MA USA </div>
<div id="Aff5">
<sup>5</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA USA </div>
<div id="Aff6">
<sup>6</sup>NeoGenomics, Inc., Fort Meyers, FL USA </div>
<div id="Aff7">
<sup>7</sup>Center for Engineering in Medicine &amp; Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA </div>
<div id="Aff8">
<sup>8</sup>Department of Pathology, Massachusetts General Hospital, Boston, MA USA </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>âœ‰</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 24; Accepted 2025 Aug 4; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Â© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the articleâ€™s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articleâ€™s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12373877Â Â PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40846896/" class="usa-link">40846896</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>
<strong>Previous version available:</strong> This article is based on a previously available preprint posted on medRxiv on January 28, 2025: "<a href="/articles/PMC11838965/" class="usa-link">Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer</a>".</div></div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive disease with limited predictive biomarkers, often leading to ineffective treatments and unnecessary toxicity. Circulating tumor DNA (ctDNA) provides a promising real-time, non-invasive tool for monitoring disease activity. In this study, we analyzed 137 plasma samples from 16 patients with R/M HNSCC receiving immune checkpoint blockade (ICB), using a tumor-informed, highly sensitive next-generation sequencing assay (RaDaR, NeoGenomics). Serial ctDNA monitoring was performed at baseline and throughout treatment, and its association with clinical outcomes, including disease control, three-year overall survival (OS), and progression-free survival (PFS), was evaluated through univariable and multivariable analyses. ctDNA negativity during treatment was significantly associated with improved disease control (OR 21.7, 95% CI 1.86â€“754.88, <em>p</em>â€‰=â€‰0.0317), three-year OS (HR 0.04, 95% CI 0.00â€“0.47, <em>p</em>â€‰=â€‰0.0103), and PFS (HR 0.03, 95% CI 0.00â€“0.37, <em>p</em>â€‰=â€‰0.0057). Early increases in ctDNA levels correlated with disease progression. Our findings suggest that ctDNA negativity, regardless of PD-L1 expression, ICB regimen, or line of therapy, is a strong predictor of favorable outcomes in R/M HNSCC.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Subject terms:</strong> Head and neck cancer, Biomarkers, Predictive markers, Oncology, Cancer immunotherapy</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par2">Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive cancer. Only a minority of patients benefit from the current standard-of-care options, including first-line therapies, which for most patients consist of immune checkpoint blockade (ICB) with or without concurrent cytotoxic chemotherapy. Pembrolizumab, either alone or combined with chemotherapy, significantly improves survival compared to cetuximab plus chemotherapy in R/M HNSCC patients, in particular those with a PD-L1 combined positive score (CPS)â€‰â‰¥â€‰1 (median 12.3 months versus 10.3 months) and CPSâ€‰â‰¥â€‰20 (median 14.9 months versus 10.7 months). However, objective response rates (ORR) remain suboptimal. While CPS correlates with response (e.g., ORR of 4.5% versus 14.5% for monotherapy, and 31% versus 34% for combination therapy in CPS &lt;1 versus CPS 1â€“19 subgroups), the vast majority (66â€“95%) of patients fail to respond to ICB-based therapy<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>â€“<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup>. Unsurprisingly, the prognosis remains poor, highlighting a clear unmet need to develop biomarker-informed therapeutic approaches for patients with R/M HNSCC<sup><a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup>. Despite its clear limitations as a predictive biomarker in R/M HNSCC<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup>, PD-L1 is currently the only FDA-approved predictive biomarker to aid clinical decision-making in R/M HNSCC<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a></sup>. Additionally, as a static biomarker<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a></sup>, PD-L1 is only useful for predicting outcomes at the time of treatment initiation and cannot assist in clinical decision-making once a patient has started treatment. This underscores the need for dynamic, non-invasive biomarkers that can provide ongoing insights into disease status, enabling clinicians to tailor treatment decisions in real time.</p>
<p id="Par3">Patients with R/M HNSCC resistant to ICB and surgically salvageable disease who either previously declined surgical approaches or, due to cytoreduction from ICB-based therapy, have lesion(s) that have become amenable to surgical resection, may experience better local control with the application of salvage local therapy<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>,<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a></sup>. A non-invasive biomarker measured serially during therapy has the potential to augment the assessment of disease status to aid clinicians in personalizing the addition of localized treatment modalities (i.e., surgery or radiotherapy) to systemic therapy, moving on to a new line of systemic therapy, or potentially providing a treatment holiday in the event of positive response to treatment.</p>
<p id="Par4">Liquid biopsy with tumor-informed ctDNA is a modality to monitor disease that is complementary to routine imaging methods currently used for assessing R/M HNSCC treatment response. This minimally invasive, real-time approach detects circulating tumor DNA (ctDNA) in clinically accessible biofluids, offering potential utility for treatment response assessment in the metastatic setting<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>â€“<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup>. ctDNA detection using next-generation sequencing (NGS) has strong predictive and prognostic potential across various solid tumors treated with ICB<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>â€“<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup>. Specifically, a decrease in ctDNA levels after one cycle of ICB has been associated with improved OS and progression-free survival (PFS) in multiple solid tumors<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>. Importantly, ctDNA changes after one cycle of ICB have shown strong prognostic potential for both OS and PFS in HNSCC using tumor-naive and tumor-informed ctDNA detection methods<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>,<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup>. Similar results have been observed in patients with non-small cell lung cancer (NSCLC)<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>â€“<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a></sup>, colorectal cancer<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>, urothelial cancer<sup><a href="#CR20" class="usa-link" aria-describedby="CR20">20</a></sup>, and human papillomavirus (HPV)-associated cancers such as cervical<sup><a href="#CR21" class="usa-link" aria-describedby="CR21">21</a></sup> and anal squamous cell carcinoma<sup><a href="#CR22" class="usa-link" aria-describedby="CR22">22</a></sup>.</p>
<p id="Par5">Beyond estimating survival, ctDNA detection has also shown promising results in predicting disease progression in patients with HNSCC undergoing ICB. In a cohort of fourteen patients, tumor-informed ctDNA changes correlated with disease status, with decreasing ctDNA levels during treatment for responders and increasing levels for non-responders<sup><a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup>. However, the approaches utilized in this study had a limit of detection of 0.01% (measured in estimated variant allele frequency [%eVAF]), limiting the ability to detect microscopic residual disease. ctDNA assays with improved sensitivity are needed to improve the accuracy of ctDNA monitoring. These data underscore the potential for measurement of early on-treatment ctDNA dynamics to augment the estimation of anti-tumor response to ICB for patients with R/M HNSCC.</p>
<p id="Par6">Because PD-L1 is both a weak predictive biomarker in HNSCC at the time of diagnosis and is not of utility in monitoring response to ICB, there is a critical need to develop and validate novel non-invasive and effective biomarkers. ctDNA detection approaches have shown promise but have been limited in their sensitivity. We therefore elected to perform this prospective single-institution study in which we applied a tumor-informed, tenfold more sensitive (Limit of Detection, LoD95: 0.0011%) NGS liquid biopsy assay<sup><a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>,<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a></sup> to assess ctDNA dynamics in patients with R/M HNSCC as a biomarker of response to ICB-based therapy. We hypothesized that (1) ctDNA becoming undetectable during treatment would be associated with improved OS and PFS, while (2) persistent ctDNA detection would identify patients who will progress on ICB for R/M HNSCC.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Patient baseline characteristics</h3>
<p id="Par7">One hundred thirty-seven blood samples were collected between January 2021 and December 2022, with a median of 6.5 samples per patient (range: 3â€“20) from sixteen patients with R/M HNSCC being treated with ICB therapy. The median age was 62 years old (range: 52â€“91). The oral cavity was the most common anatomic subsite (8/16, 50%), and most patients received pembrolizumab monotherapy (11/16, 69%). Most patients had a CPS â‰¥20 (11/16, 69%). Among patients with virally-driven tumors, three patients had HPV-associated oropharyngeal carcinoma (OPC), one patient had HPV-associated nasopharyngeal carcinoma (NPC), and one patient had Epstein-Barr Virus (EBV)-associated NPC.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Plasma ctDNA testing results</h3>
<p id="Par8">The overall ctDNA detection rate across all samples was 57% (78/137) (Fig. <a href="#Fig1" class="usa-link">1</a>A, B). The median %eVAF was 0.1399 (range: 0.0007â€“7.0738) (Table <a href="#MOESM1" class="usa-link">S1</a>). Patient baseline characteristics are summarized in Table <a href="#Tab1" class="usa-link">1</a>. 88% (14/16) of patients had a pre-ICB plasma sample (considered the baseline sample for this study) available for analysis (Patients 02, 03, 06, 08, 09, 10, 13, 14, 15, 18, 19, 20, 25, 26) with 12/14 (85.7%) being ctDNA positive (Patients 02, 03, 06, 08, 09, 10, 13, 14, 19, 20, 25, 26; median %eVAF: 0.28, range: 0.004â€“1.8). The two patients with negative baseline ctDNA had regionally or distant metastatic oral cavity SCC: Patient-15 had an enlarging 2.5â€‰Ã—â€‰1.5â€‰cm lung mass, and Patient-18 had a 4.1â€‰Ã—â€‰5.5â€‰Ã—â€‰5.7â€‰cm cystic neck mass.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1. Tumor-informed ctDNA workflow and swimmer plot for the entire cohort.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373877_41698_2025_1084_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b992/12373877/89314553bbec/41698_2025_1084_Fig1_HTML.jpg" loading="lazy" id="d33e481" height="986" width="800" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> Pretreatment FFPE tumor tissue from patients with HPV-independent HNSCC undergoing ICB therapy was obtained. DNA was extracted specimens with &gt;20% of tumor component, and WES was performed to identify somatic mutations used to create personalized assays (RaDaR) for each patient. Plasma was obtained before and during ICB treatment, and each plasma sample was assessed for ctDNA detection. <strong>B</strong> Swimmer plot shows longitudinal monitoring of ctDNA, treatment, and response. CR complete response, PD progressive disease, PR partial response, SD stable disease. Patients 6, 8, 10 and 14 received a combination of immunotherapy plus chemotherapy. Patient 7 received Pembrolizumab plus ALX148 (anti-CD47).</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Clinical characteristics of the cohort</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Total cases</th>
<th colspan="1" rowspan="1">16</th>
</tr></thead>
<tbody>
<tr><td colspan="2" rowspan="1"><strong>Sex</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒMale</td>
<td colspan="1" rowspan="1">13</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒFemale</td>
<td colspan="1" rowspan="1">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Age, median (range, year)</strong></td>
<td colspan="1" rowspan="1">62 (52â€“91)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ&lt;65</td>
<td colspan="1" rowspan="1">11</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒâ‰¥65</td>
<td colspan="1" rowspan="1">5</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Anatomic site</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒOropharynx</td>
<td colspan="1" rowspan="1">4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒOral cavity</td>
<td colspan="1" rowspan="1">8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒNasopharynx</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒUnknown primary</td>
<td colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒNasal cavity</td>
<td colspan="1" rowspan="1">1</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>ECOG performance status</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ0</td>
<td colspan="1" rowspan="1">5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ1</td>
<td colspan="1" rowspan="1">8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ2</td>
<td colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ3</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ4</td>
<td colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒUnknown</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Treatment</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒPembrolizumab</td>
<td colspan="1" rowspan="1">11</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒPembrolizumab + combinational therapy*</td>
<td colspan="1" rowspan="1">5</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Tobacco use</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒNever</td>
<td colspan="1" rowspan="1">11</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒFormer</td>
<td colspan="1" rowspan="1">5</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Alcohol consumption</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒCurrent</td>
<td colspan="1" rowspan="1">9</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒFormer</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒNever</td>
<td colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒUnknown</td>
<td colspan="1" rowspan="1">4</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Stage</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒPrimary</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒLocoregional recurrent</td>
<td colspan="1" rowspan="1">7</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒDistant recurrence</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒLocoregional + distant recurrence</td>
<td colspan="1" rowspan="1">5</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>CPS</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ&lt;1</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ1â€“19</td>
<td colspan="1" rowspan="1">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒâ‰¥20</td>
<td colspan="1" rowspan="1">11</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Local therapy following ICB start</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒYes**</td>
<td colspan="1" rowspan="1">3</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒNo</td>
<td colspan="1" rowspan="1">13</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Number of prior lines of systemic therapy</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ0</td>
<td colspan="1" rowspan="1">13</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ1â€“2</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ&gt;2</td>
<td colspan="1" rowspan="1">1</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Number of infusions</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒâ‰¤5</td>
<td colspan="1" rowspan="1">10</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒ10â€“20</td>
<td colspan="1" rowspan="1">4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒâ‰¥21</td>
<td colspan="1" rowspan="1">2</td>
</tr>
<tr><td colspan="2" rowspan="1"><strong>Viral status</strong></td></tr>
<tr>
<td colspan="1" rowspan="1">â€ƒHPV</td>
<td colspan="1" rowspan="1">4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒEBV</td>
<td colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">â€ƒNegative</td>
<td colspan="1" rowspan="1">11</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p11"><p>*Pembrolizumab + chemotherapy: <em>n</em>â€‰=â€‰4; Pembrolizumab + anti-CD47: <em>n</em>â€‰=â€‰1; **Salvage surgery: <em>n</em>â€‰=â€‰1; Salvage radiation <em>n</em>â€‰=â€‰2.</p></div></div></section><p id="Par9">The cohort consisted predominantly of patients belonging to LB-RECIST response Group 1 (detectable ctDNA that remains detectable after therapy; <em>n</em>â€‰=â€‰9; Patients 02, 03, 06, 07, 09, 13, 14, 19, 26) or Group 2 (detectable ctDNA that became undetectable after therapy; <em>n</em>â€‰=â€‰4; Patients 08, 10, 20, 25). One patient was classified as Group 3 (undetectable ctDNA at baseline that becomes detectable after therapy; Patient-15), and two patients were classified as Group 4 (undetectable ctDNA that remains undetectable after therapy; Patients 18, 23). Additionally, based on the quantitative response criteria categories, most patients showed ctDNA progressive disease (CPD; <em>n</em>â€‰=â€‰8; Patients 02, 03, 07, 09, 13, 14, 15, 26), which is defined as an increase of &gt;10% in eVAF or de novo ctDNA detection. The four patients belonging to LB-RECIST Group 2 were defined as having experienced a ctDNA complete response, defined as ctDNA clearance after initial detection<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>,<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a></sup> (Table <a href="#Tab2" class="usa-link">2</a>). The median follow-up time was 19 months (range: 1.5â€“42.6). When defining response by RECIST 1.1 or clinical assessment (if RECIST was not evaluable), there were two patients with best ORR of complete response (12%, CR), four patients with partial response (25%, PR), two patients with stable disease (12%, SD), and eight patients with progressive disease (50%, PD) (Table <a href="#Tab2" class="usa-link">2</a>). The median time to achieve ctDNA negativity was 2.5 months (range 0.7â€“20.6), and the median time for ctDNA detection after clearance was 7 months (range 1.3â€“9.3). Three patients died from progressive disease soon after starting ICB therapy (Patients 09, 13, 26). For the remaining thirteen patients, a median of 1 (range 0 to 5) subsequent line of treatment was received (including systemic therapy and salvage or palliative local therapy) following disease progression on ICB therapy. A median of four ICB infusions were administered (range 2â€“35), and a median of 13 months (range 1.3â€“27) elapsed from ICB initiation until death from any cause.</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>LB-RECIST and radiological RECISTv1.1 in the cohort</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">LB-RECIST group</th>
<th colspan="1" rowspan="1">Definition</th>
<th colspan="1" rowspan="1">
<em>N</em> (%) LB-RECIST</th>
<th colspan="1" rowspan="1">Patients</th>
<th colspan="1" rowspan="1">RECIST v1.1</th>
<th colspan="1" rowspan="1">
<em>N</em> (%)</th>
<th colspan="1" rowspan="1">Patients</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">D -&gt;â€‰D</td>
<td colspan="1" rowspan="1">9/16 (56)</td>
<td colspan="1" rowspan="1">02, 03, 06, 07, 09, 13, 14, 19, 26</td>
<td colspan="1" rowspan="1">PD</td>
<td colspan="1" rowspan="1">8/16 (50)</td>
<td colspan="1" rowspan="1">02, 03, 07, 09, 13, 14, 15, 26</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">D -&gt;â€‰U</td>
<td colspan="1" rowspan="1">4/16 (25)</td>
<td colspan="1" rowspan="1">08, 10, 20, 25</td>
<td colspan="1" rowspan="1">SD</td>
<td colspan="1" rowspan="1">2/16 (12)</td>
<td colspan="1" rowspan="1">06, 19</td>
</tr>
<tr>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">U -&gt;â€‰D</td>
<td colspan="1" rowspan="1">1/16 (6)</td>
<td colspan="1" rowspan="1">15</td>
<td colspan="1" rowspan="1">PR</td>
<td colspan="1" rowspan="1">4/16 (25)</td>
<td colspan="1" rowspan="1">10, 18, 20, 25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">4</td>
<td colspan="1" rowspan="1">U -&gt;â€‰U</td>
<td colspan="1" rowspan="1">2/16 (12)</td>
<td colspan="1" rowspan="1">18, 23</td>
<td colspan="1" rowspan="1">CR</td>
<td colspan="1" rowspan="1">2/16 (12)</td>
<td colspan="1" rowspan="1">08, 23</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p14"><p>Group 1: Patients with detectable ctDNA which remains detectable after therapy; Group 2: Patients with detectable ctDNA which became undetectable after therapy; Group 3: Patients with undetectable ctDNA which became detectable after therapy; Group 4: Patients with undetectable ctDNA which remained undetectable after therapy. <em>D</em> Detectable, <em>U</em> Undetectable<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>. RECIST v1.1 was able to be applied in 14 cases. For two patients, imaging was not available, and clinical assessment was used. <em>PD</em> progressive disease, <em>SD</em> stable disease, <em>PR</em> partial response, <em>CR</em> complete response.</p></div></div></section><p id="Par10">Eight patients (Patients 02, 03, 06, 07, 08, 10, 14, 15) had samples available after stopping ICB. Seven halted ICB due to PD, whereas one patient stopped ICB due to adverse events but showed no evidence of recurrence (Patient-08). Among those who developed PD, three (Patients 03, 06, 15) proceeded to multimodality therapy and demonstrated a decline in ctDNA to undetectable levels. By contrast, the remaining four patients with disease not amenable to salvage local therapy (Patients 02, 07, 10, 14) exhibited an increase in ctDNA levels immediately after stopping ICB. Notably, in the patient who had achieved a complete response from ICB (Patient-08), ctDNA levels remained undetectable following cessation of ICB. Lead time from ctDNA clearance to corresponding imaging response could not be accurately assessed because blood sample collection for ctDNA analysis and imaging assessment only coincided for a small selection of patients.</p></section><section id="Sec5"><h3 class="pmc_sec_title">ctDNA negativity predicts disease control</h3>
<p id="Par11">Among the four patients who experienced a ctDNA CR (LB-RECIST Group 2; Patients 08, 10, 20, 25), one had a RECIST 1.1 CR (Patient-08), and three had RECIST 1.1 PR (Patients 10, 20, 25) (Fig. <a href="#MOESM1" class="usa-link">S1</a>, Table <a href="#MOESM1" class="usa-link">S2</a>). Importantly, those patients experienced ctDNA clearance due to ICB. Two of those four patients (Patients 08, 20) experienced immune-related adverse events (colitis and pneumonitis) after 1 and 1.5 years on ICB, respectively. In univariable analyses, we found that neither ICB regimen, CPS, nor line of therapy were predictive of ctDNA clearance. Early on ICB therapy, the sensitivity and specificity of ctDNA negativity to predict an overall response (CR or PR) were 75% and 100%, respectively. Patients without pre-ICB sample available (<em>n</em>â€‰=â€‰2) and with persistently negative ctDNA levels (<em>n</em>â€‰=â€‰1) were also included in the analysis. For this analysis, ctDNA was assessed after a median of two infusions (range 1 to 7) and within a mean of 13 days (range â€“4 to 142) of radiological (<em>n</em>â€‰=â€‰14) or clinical (<em>n</em>â€‰=â€‰2) confirmation of RECIST 1.1 assessment. Interestingly, two patients (Patients 06, and 19) were classified as having stable disease (SD) despite a positive ctDNA result (Table <a href="#Tab3" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Radiographic and ctDNA molecular response</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th rowspan="2" colspan="1">Best objective response</th>
<th colspan="1" rowspan="1">Molecular response</th>
<th colspan="1" rowspan="1">Sensitivity</th>
<th rowspan="2" colspan="1">Specificity</th>
<th rowspan="2" colspan="1"></th>
</tr>
<tr>
<th colspan="1" rowspan="1">ctDNA-</th>
<th colspan="1" rowspan="1">ctDNAâ€‰+â€‰</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">CR/PR</td>
<td colspan="1" rowspan="1">6</td>
<td colspan="1" rowspan="1">2</td>
<td rowspan="2" colspan="1">100%</td>
<td rowspan="2" colspan="1">75%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PD</td>
<td colspan="1" rowspan="1">0</td>
<td colspan="1" rowspan="1">8</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p18"><p>ctDNA results after two infusions (range 1 to 7) and within 13 days of RECIST assessment (range â€“4 to 142). <em>CR</em> Complete response, <em>PR</em> partial response, <em>SD</em> stable disease, <em>PD</em> progressive disease.</p></div></div></section><p id="Par12">We performed logistic regression analyses to assess undetectable ctDNA as a predictor of treatment response ([1] ORR: CR/PR versus SD/PD; and [2] disease control: CR/PR/SD versus PD). In univariable analysis, undetectable ctDNA at any time during the study period (either pre-treatment or on-treatment) was predictive of a 21-fold increase in odds of achieving disease control (CR, PR, or SD) (95% CI 2.04â€“558.55, <em>p</em>â€‰=â€‰0.0236). This association remained significant in multivariable analyses controlling for PD-L1, ICB regimen, and line of therapy (OR 21.7, 95% CI 1.86â€“754.88, <em>p</em>â€‰=â€‰0.0317). To ensure these results were not driven by the two patients in our cohort belonging to LB-RECIST Group 4 (patients who never had detectable ctDNA), we performed a sensitivity analysis by excluding Patients 18 and 23 and observed that this finding persisted (univariable OR 15, 95% CI 1.37â€“408.3, <em>p</em>â€‰=â€‰0.04; multivariable OR 14.5, 95% CI 1.06â€“560.5, <em>p</em>â€‰=â€‰0.07).</p></section><section id="Sec6"><h3 class="pmc_sec_title">Undetectable ctDNA predicts improved overall and progression-free survival</h3>
<p id="Par13">Across all patients, the median OS was 19.9 months, and the median PFS was 2.7 months (Fig. <a href="#Fig2" class="usa-link">2</a>A, B) from ICB initiation. In univariable analyses, we found no difference in OS or PFS when stratified by ICB regimen, CPS, recurrence type (locoregional versus distant versus both), primary anatomical site, or virus (HPV or EBV) status. In our cohort, five patients received combined treatment (Patients 06, 07, 08, 10, 14). Four patients received ICB combined with chemotherapy (Patients 06, 08, 10, 14), and one received a combination of ICB and an experimental anti-CD47 antibody therapy (Patient-07). We analyzed the survival and response outcomes for those subpopulations and found no difference among groups for OS (HR 1.87, 95% CI 0.49â€“7.13; <em>p</em>â€‰=â€‰0.35), or PFS (HR 0.93, 95% CI 0.28â€“3.04; <em>p</em>â€‰=â€‰0.91). However, ctDNA negativity was found to be a significant predictor of improved OS and PFS. In univariable analyses, patients who had undetectable ctDNA at any point during the study period, including patients who were always negative during the study period (Patients 18, and 23; LB-RECIST Group 4), had better OS (HR 0.10, 95% CI 0.02â€“0.48, <em>p</em>â€‰=â€‰0.001) and PFS (HR 0.17, 95% CI 0.04â€“0.69, <em>p</em>â€‰=â€‰0.006). In multivariable analyses controlling for CPS, ICB regimen, viral status, and recurrence type, the association remained significant for both OS (HR 0.04, 95% CI 0.00â€“0.47, <em>p</em>â€‰=â€‰0.0103) and PFS (HR 0.03, 95% CI 0.00â€“0.37, <em>p</em>â€‰=â€‰0.0057) (Fig. <a href="#Fig2" class="usa-link">2</a>C, D). We again performed a sensitivity analysis to ensure these results were not driven by patients who were always ctDNA negative during the study period by excluding these two patients (Patients 18 and 23) and found that the findings persisted (univariable HR for OS 0.17, 95% CI 0.03â€“0.86, <em>p</em>â€‰=â€‰0.0321; multivariable HR for OS 0.05, 95% CI 0â€“0.06, <em>p</em>â€‰=â€‰0.0175; univariable HR for PFS 0.23, 95% CI 0.06â€“0.94, <em>p</em>â€‰=â€‰0.0411; multivariable HR for PFS 0.05, 95% CI 0â€“0.61, <em>p</em>â€‰=â€‰0.019). Additionally, when limiting our analysis to patients who achieved ctDNA negativity exclusively through ICB, we observed a consistent association with improved outcomes. Three-year overall survival (OS) was 75% compared to 20% in those who did not clear ctDNA (median OS: 28 versus 22 months; <em>p</em>â€‰&lt;â€‰0.02, Log-Rank test). Similarly, three-year PFS was 50% versus 0% (median PFS: 9 versus 3 months; <em>p</em>â€‰&lt;â€‰0.003, Log-Rank test) (Fig. <a href="#MOESM1" class="usa-link">S2</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2. Three-year overall survival and progression-free survival for the entire cohort.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373877_41698_2025_1084_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b992/12373877/cf0603e2f1e8/41698_2025_1084_Fig2_HTML.jpg" loading="lazy" id="d33e1108" height="753" width="800" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> Overall survival for the entire cohort. <strong>B</strong> Progression-free survival for the entire cohort. <strong>C</strong> Overall survival based on ctDNA negativity at any point during the study period based on multivariable analysis. <strong>D</strong> Progression-free survival based on ctDNA negativity at any point during the study period based on multivariable analysis.</p></figcaption></figure><p id="Par14">ctDNA yielded comparable prognostic capability obtained with imaging-based prediction of OS. When response was determined by radiographic (RECIST 1.1) or clinical (when imaging was unavailable) assessment, an objective response (CR or PR) was associated with improved OS (HR 0.12, 95% CI 0.01â€“0.98, <em>p</em>â€‰=â€‰0.04) while disease control (CR, PR, or SD) trended toward improved OS (HR 0.28, 95% CI 0.07â€“1.64, <em>p</em>â€‰=â€‰0.08).</p></section><section id="Sec7"><h3 class="pmc_sec_title">Early %eVAF increase is a key marker for disease progression</h3>
<p id="Par15">We evaluated the association between changes in ctDNA levels from P1 to P2 (after a median of 1 dose of ICB) and best ORR using penalized logistic regression to account for the small sample size. We assessed various ctDNA dynamics parametersâ€”(1) absolute change in %eVAF, and thresholds of both (2) &gt;20% and (3) &gt;50% change in ctDNA levels from the pre-treatment to first on-treatment measurement after a median of one cycle (data not shown)â€”and found a strong association between absolute change in ctDNA (increase in ctDNA from P1 to P2) and disease progression at first treatment response assessment after starting ICB (Fisherâ€™s exact test <em>p</em>â€‰=â€‰0.0047; Phi coefficient = 0.85) (Fig. <a href="#Fig3" class="usa-link">3</a>A). Among patients with an increase in ctDNA levels from P1 to P2 (Patients 02, 03, 09, 13, 14, 15, 25, 26), 87% (7/8) of patients experienced disease progression at their first treatment response assessment. In contrast, none of the patients with a decrease in ctDNA levels (Patients 06, 08, 10, 19, 20) experienced PD at first treatment response assessment. Of note, three patients (07, 18, and 23) were not included in the analysis because either no pretreatment sample was available for analysis or both P1 and P2 samples were negative.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3. Increased ctDNA from P1 to P2 is associated with disease progression.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373877_41698_2025_1084_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b992/12373877/d691d8a24140/41698_2025_1084_Fig3_HTML.jpg" loading="lazy" id="d33e1140" height="348" width="700" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> Distribution of best objective response rate (CR/PR/SD versus PD) stratified by changes in ctDNA levels between P1 and P2. <strong>B</strong> Forest plot showing that an increase in ctDNA levels from P1 to P2 is independently associated with disease progression, regardless of CPS (0 or &lt;1, 1â€“19, and â‰¥20) and treatment regimen (monotherapy versus combination therapy).</p></figcaption></figure><p id="Par16">To further evaluate the independent association while accounting for potential confounders, we performed multivariable logistic regression using Firthâ€™s penalized likelihood approach. After adjusting for CPS and treatment regimen (ICB vs chemo/ICB), an increase in ctDNA levels from P1 to P2 remained significantly associated with disease progression as best ORR (adjusted OR 28.4; 95% CI 1.74â€“7613.5; <em>p</em>â€‰=â€‰0.016). Neither CPS (adjusted OR 4.65; 95% CI 0.001â€“3.89; <em>p</em>â€‰=â€‰0.37) nor treatment regimen (adjusted OR 1.23; 95% CI 0.003â€“338.8; <em>p</em>â€‰=â€‰0.93) were significantly associated with disease progression (Fig. <a href="#Fig3" class="usa-link">3</a>B).</p></section></section><section id="Sec8"><h2 class="pmc_sec_title">
<strong>D</strong>iscussion</h2>
<p id="Par17">This study evaluated the clinical utility of a tumor-informed WES-based liquid biopsy assay in predicting ORR, OS, PFS, and PD in patients with R/M HNSCC receiving ICB-based therapy. Using serial ctDNA monitoring, we found ctDNA negativity to be strongly associated with survival outcomes and disease control, regardless of CPS, ICB regimen, and line of therapy. Furthermore, we found a strong association between an early increase in %eVAF and disease progression, regardless of CPS or treatment regimen.</p>
<p id="Par18">In our cohort, patients were ctDNA negative through one of three ways: (1) patients who never had detectable ctDNA (LB-RECIST Group 4), (2) after ICB therapy (LB-RECIST Group 2), or (3) following salvage multimodality therapy (i.e., surgery or radiation) after progression on ICB (LB-RECIST Group 2). Having an undetectable ctDNA level conferred both an OS and PFS advantage irrespective of when the transition to becoming ctDNA undetectable occurred, including patients whose ctDNA was undetectable at baseline (OS HR 0.05, PFS HR 0.05). We also found that an increase in %eVAF early on treatment was strongly associated with disease progression at the time of first treatment response evaluation after starting ICB as determined by radiographic or clinical assessment. Taken together, these findings suggest that a tumor-informed liquid biopsy assay may aid clinicians in identifying patients with R/M HNSCC who might benefit from treatment escalation or next-line therapy, although this approach would need to be validated in future prospective studies.</p>
<p id="Par19">Our study recapitulates findings reported in other solid tumor types, including NSCLC, uveal melanoma, and microsatellite-unstable colorectal cancer<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>,<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>,<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup>. In these studies, the molecular response, as measured by serial ctDNA monitoring, was associated with radiographic response<sup><a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup>. For example, in a phase 2 clinical trial evaluating ctDNA in NSCLC, molecular response to ICB and chemotherapy showed a sensitivity of 82% and a specificity of 75% compared to RECIST 1.1 criteria as the gold standard<sup><a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup>. Our data indicated that this ctDNA assay is associated with comparable test characteristics, with a slightly lower sensitivity of 75% and a slightly higher specificity of 100% in HNSCC, noting that these results should be interpreted in the context of a limited sample size. Importantly, in contrast to the cohort presented here, molecular response was assessed in the NSCLC cohort after three cycles of ICB, and the median time to ctDNA negativity was 2.1 months compared with a median of two doses of ICB and 2.5 months in our cohort, respectively.</p>
<p id="Par20">Acknowledging the limitations of small sample size despite an impressive average number of samples collected per patient, we felt it prudent to verify that the association between ctDNA dynamics and ORR, OS, and PFS was not driven by the small subset of patients whose ctDNA was undetectable for the entire study period (LB-RECIST Group 4; Patients 18 and 23). In this sensitivity analysis, we re-ran all analyses, excluding these two patients, and observed similar results. The reason for undetectable ctDNA in these two patients is not clear but could be related to a low overall disease burden relative to other patients in the study, a low tumor proliferation rate, or low shedding tumor<sup><a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>. Additionally, one patient (Patient-23) had already received seven infusions before the first sample was available, potentially explaining persistent ctDNA negativity. Overall, these data align with prior reports that indicate having undetectable ctDNA at any time (LB-RECIST Groups 2 and 4) is associated with improved survival<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>,<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup>. Using the LB-RECIST classification system during our analysis helped to ensure a robust and systematic assessment of these data and highlighted the utility of such a classification system to aid in a structured and comprehensive approach to analyzing ctDNA data sets. This is particularly important as ctDNA monitoring becomes even more commonplace in both experimental and standard of care clinical practice. However, as the LB-RECIST classification system has not been prospectively validated, it is important to recognize its limitations. For example, evolving assay sensitivity can bias this classification system as discordant results from the same blood sample can occur when using different methods of ctDNA detection<sup><a href="#CR30" class="usa-link" aria-describedby="CR30">30</a></sup>. Therefore, harmonizing the collection and interpretation of ctDNA data across studies will strengthen the rationale for incorporating ctDNA monitoring into clinical practice across cancer types, disease settings, and treatment regimens.</p>
<p id="Par21">Based on the results presented here, serial, tumor-informed, WES-based ctDNA monitoring has the potential to provide patients with prognostic information that is more accurate than the summary statistics typically reported by major clinical trials. This approach could also guide clinicians in tailoring subsequent treatment options for patients who fail to achieve undetectable ctDNA during ICB. Importantly, the turnaround time for all samples was 49 days. However, for prospective studies, NeoGenomics has a turnaround time of 30 days for WES plus panel design and qualification and 7â€“10 days for follow-up timepoints, highlighting the clinical utility of this approach for patients recieving systemic therapy.</p>
<p id="Par22">Evidence suggests that escalation with multimodality interventions in the absence of molecular response can improve survival outcomes. For instance, although the SABR-COMET trial did not use ctDNA to determine eligibility, it demonstrated that stereotactic ablative radiotherapy in oligometastatic disease confers an overall survival advantage in multiple solid tumor types, including breast, lung, colorectal, and prostate cancers<sup><a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>. Incorporating serial ctDNA monitoring could serve as a valuable tool to better select patients with metastatic disease for local therapies, thereby optimizing treatment strategies and outcomes.</p>
<p id="Par23">In addition to assessing the binary outcome of detectable/undetectable ctDNA, we also sought to characterize the predictive capability of ctDNA dynamics. We assessed various ctDNA dynamics parametersâ€”absolute change in %eVAF after a median of one cycle, and thresholds of both &gt;20% and &gt;50% change in ctDNA levels from the pre-treatment to first on-treatment measurement (data not shown)â€”and found an association between an absolute increase in %eVAF early on treatment and disease progression. Our findingsâ€”ctDNA response was associated with improved outcomes, and rising ctDNA from P1 to P2 was associated with progressive diseaseâ€”recapitulate data from Bratman et al. who demonstrated an association between early ctDNA dynamics and treatment response. In that study, decreasing ctDNA from baseline to after 3 cycles of pembrolizumab was associated with an increased chance of objective response of CR or PR (OR 28.74, 95% CI 3.51â€“253.04) in a large cohort of patients with a mixture of advanced solid tumors (<em>n</em>â€‰=â€‰94, HNSCC <em>n</em>â€‰=â€‰14)<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup>, while any rise in ctDNA levels during surveillance above baseline was associated with rapid disease progression and poor survival<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup>. Although ctDNA monitoring shows promise as a predictor of PD, it remains an imperfect test. For one patient in this cohort (Patient-20), ctDNA was detected six days after imaging detection of PD, yet it was undetectable 15 days prior to imaging confirmation of PD. This finding underscores the importance of interpreting ctDNA results as complementary to, rather than a replacement for, current imaging approaches, thereby reducing the risk associated with false negative ctDNA results or the inability of even highly sensitive assays to detect rapidly evolving disease progression<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>,<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>.</p>
<p id="Par24">Our study has multiple limitations. First, a limited cohort size and the heterogeneity of the patient population (e.g., ICB regimen, a mixture of virus-associated and virus-independent tumors, CPS), limit the interpretation of our findings. Second, because samples were collected during routine clinical visits, our study did not apply a fixed schedule for sample collection. This limitation should also be interpreted with the context that the optimal timing of serial ctDNA measurements for different systemic therapy regimens (e.g., ICB versus chemotherapy plus ICB) or tumor types is not known<sup><a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>. Third, all clinical data were annotated retrospectively, possibly introducing retrospective bias. Lastly, although we applied a proprietary technology to characterize the serial ctDNA dynamics by defining an absolute change in the abundance of eVAF% as clinically significant, the minimum clinically meaningful change in ctDNA levels between samples in patients with HNSCC has not yet been clearly defined<sup><a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>.</p>
<p id="Par25">While this study does not establish the definitive clinical utility of personalized ctDNA in R/M HNSCC, our findings support the integration of ctDNA analysis in two key contexts for future research. First, to evaluate the potential benefit of a treatment holiday for patients who achieve ctDNA negativity, and second, to explore the role of either a change in systemic therapy if ctDNA negativity is not achieved, or the transition to multimodality therapy (i.e., radiation and/or surgery) with or without systemic therapy for patients who remain ctDNA-positive but may be candidates for an intensified therapeutic approach aimed at achieving ctDNA clearance.</p>
<p id="Par26">In summary, using serial ctDNA monitoring, we found ctDNA negativity to be strongly associated with disease control and improved survival, and rising ctDNA between the pre-treatment and first on-treatment timepoints to be associated with progressive disease in patients with R/M HNSCC treated with ICB. This study supports the role of ctDNA as a real-time biomarker to inform future prospective studies aimed at evaluating both treatment intensification and de-intensification approaches to improve survival and patient quality of life.</p></section><section id="Sec9"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec10"><h3 class="pmc_sec_title">Patient recruitment</h3>
<p id="Par27">Patients were eligible for this study if they started treatment for R/M HNSCC (oropharyngeal, oral cavity, nasopharyngeal, sinonasal, laryngeal, or hypopharyngeal anatomical primary sites, as well as unknown primaries) at Massachusetts General Hospital Cancer Center (MGHCC) with systemic anti-neoplastic therapy containing ICB between January 2021 and December 2022. Archival FFPE tumor tissue was reviewed and confirmed by a head and neck pathologist (A.S.F). Sixteen patients were enrolled in this study. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (DFCI 18â€“653). Written informed consent was obtained from all patients.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Clinical specimens</h3>
<p id="Par28">Serial blood samples were prospectively collected before, during, and after ICB treatment when blood was being drawn for clinical purposes, whenever possible, between January 2021 and December 2022. Due to the inherent nature of clinical care, blood for ctDNA analysis was not collected on a fixed schedule across all patients in this observational study. Blood samples were drawn in EDTA tubes, and plasma was obtained after two rounds of centrifugation (10â€‰min at 1600 RCF and 3000 RCF). Plasma and buffy coat were then aliquoted and stored at â€“80â€‰Â°C. Blood samples collected before and during treatment were available for prospective plasma ctDNA testing, while clinical data were annotated retrospectively following plasma testing completion. ORR was investigator-assessed using RECIST 1.1 or by retrospective review of physical examination data in clinical notes when imaging was unavailable (Table <a href="#MOESM1" class="usa-link">S2</a>). To ensure clear communication of each patientâ€™s ctDNA kinetics, we classified patients according to the liquid biopsy response evaluation criteria in solid tumors (LB-RECIST) proposed by Gouda et al.<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup> in which four key patterns of ctDNA kinetics can be observed. OS, PFS, and ORR outcomes were evaluated, and patients were followed for clinical outcomes until a censor date of August 16th, 2024.</p></section><section id="Sec12"><h3 class="pmc_sec_title">Tumor-informed ctDNA detection assay (RaDaR) workflow and QC metrics</h3>
<p id="Par29">Formalin-fixed paraffin-embedded (FFPE) archival tissue sections from either tumor biopsies (<em>n</em>â€‰=â€‰2) or surgical resection specimens (<em>n</em>â€‰=â€‰14) were sent to NeoGenomics Laboratories, Inc. (Durham, NC) and processed for DNA extraction and whole-exome sequencing (WES)<sup><a href="#CR32" class="usa-link" aria-describedby="CR32">32</a></sup>. WES was performed to a median read depth of 306x (range: 112xâ€“607x) (Fig. <a href="#Fig1" class="usa-link">1</a>A). Personalized panels were successfully designed for all patients, capturing a median of 48 variants (range: 43â€“50) and released for plasma ctDNA testing with a median of 45 variants confirmed during panel QC (range: 19â€“49). Tumor-level key WES quality control metrics, the number of variants in each personalized panel, and those remaining after panel QC, as well as complete panel-specific variant information and their status in both tumor DNA and buffy coat control DNA, are provided in Tables <a href="#MOESM1" class="usa-link">S1</a>â€“<a href="#MOESM1" class="usa-link">S3</a>, respectively.</p>
<p id="Par30">Cell-free DNA (cfDNA) was extracted from a median plasma volume of 3.6â€‰mL (1.3â€“5.3â€‰mL). Personalized panels were applied to serial plasma samples to assess ctDNA status before, during, and after treatment. Control genomic buffy coat DNA was included to identify and filter out confounding germline mutations and variants arising from clonal hematopoiesis of indeterminate potential (CHIP), thus eliminating false positive calls during plasma analysis. cfDNA and buffy coat control DNA were extracted at NeoGenomics Laboratories, Inc. (Durham, NC) using a solid-phase reverse immobilization magnetic bead protocol on a Hamilton Microlab STAR automated platform as previously described<sup><a href="#CR32" class="usa-link" aria-describedby="CR32">32</a></sup>. ctDNA testing was performed using a median of 7100 amplifiable copies (range: 1000â€“20,000 copies) (Table <a href="#MOESM1" class="usa-link">S1</a>) and a median depth of 233,350 reads per variant per sample (range: 82,597â€“740,848) (Table <a href="#MOESM1" class="usa-link">S4</a>). The ctDNA status of all 137 samples tested across the 16 patients included in the study is shown in Fig. <a href="#Fig1" class="usa-link">1</a>B, alongside additional clinical information.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par31">This study assessed ctDNA negativity at any point during treatment as an independent predictor of treatment response and survival. To assess clinical and ctDNA predictors of best ORR according to RECIST 1.1, we used univariable and multivariable logistic regression models to compute odds ratios (OR) with 95% confidence intervals (95% CI). To assess the association between ctDNA and both OS and PFS, Kaplanâ€“Meier analysis was applied using the Log-rank test. We also performed univariable and multivariable Cox regressions and computed hazard ratios (HR) and 95% CI to assess the association between ctDNA negativity at any point during the study and OS and PFS regardless of the cause of ctDNA negativity (ICB or salvage intervention). The association between the increase in ctDNA levels (%eVAF) from timepoint 1 (P1) to timepoint 2 (P2) and disease progression was assessed using Fisherâ€™s Exact test with Phi coefficients. A median of one cycle of ICB was administered in this timeframe (eleven patients received one cycle of ICB before the second ctDNA measurement, two patients received two cycles of ICB before the second ctDNA measurement, and three patients were excluded from this analysis because either they had no pre-treatment samples or never had a sample positive for ctDNA). We additionally performed multivariable logistic regression using Firthâ€™s penalized maximum likelihood estimation. This approach was selected to mitigate the small sample size bias. The multivariable model included ctDNA dynamics (P1-P2: increase versus decrease), CPS (categorized as 0 or &lt;1, 1â€“19, and â‰¥20), and treatment regimen (monotherapy versus combination therapy). All values were considered statistically significant if Î±â€‰&lt;â€‰0.05. Analyses were performed using R Statistical Software (v4.3.1, R Core Team 2023), GraphPad (v10.1.2), or Python (v3.11.4). In R, the <em>aod</em> package (v1.3.3) was used to perform logistic regression, and the <em>survival</em> (v3.5.5) and <em>survminer</em> (v0.4.9) packages were used for survival analyses, which included both Kaplanâ€“Meier analysis and Cox proportional hazard model analysis.</p></section></section><section id="Sec14"><h2 class="pmc_sec_title">Supplementary information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12373877/bin/41698_2025_1084_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp.Material_Merged_revised_V4</a><sup> (956.1KB, pdf) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>RaDaR assays were provided in kind for this study by NeoGenomics Laboratories, Inc. (Durham, NC). NeoGenomics Laboratories, Inc. employees (C.P., A.C., C.M., L.G) did not participate in the design and sample collection of this study, yet they participated in the writing, review, and editing.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>D.L.F. conceptualized the investigation, provided supervision, and led the funding acquisition. Formal data analysis, including visualization, was performed by D.A.R.T., R.D.M., M.E.B.; D.A.R.T. and J.M. led the sample selection and shipping. J.M. and V.E. processed and stored the blood samples. A.S.F. identified the tumor on FFPE sections. D.A.R.T., R.D.M., T.R., M.P., J.C.P., S.L.S., C.P., L.J.W. and D.L.F. helped with review and editing. C.P., A.C., C.M. and L.G. processed WES samples and created the panel for variant detection in plasma samples. C.M. aided with data visualization. D.A.R.T. and R.D.M. wrote the original draft, and all authors performed critical reviews and revisions.</p></section><section id="notes2"><h2 class="pmc_sec_title">Data availability</h2>
<p>Data is provided within the manuscript or supplementary information files. The code used in this manuscript is publicly available: <a href="https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git</a>.</p></section><section id="notes3"><h2 class="pmc_sec_title">Code availability</h2>
<p>The underlying code used for this study is publicly available: <a href="https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git</a>.</p></section><section id="FPar1"><h2 class="pmc_sec_title">Competing interests</h2>
<p id="Par32">Daniel L. Faden receives research funding from NeoGenomics and receives salary support from NIH 5K23DE029811, R03DE03550, and 5R21CA267152. Amber Chevalier, Lisa Gates, Christodoulos Pipinikas, and Clodagh Murray were NeoGenomics employees for the duration of the study. The other authors declare no Competing Financial or Non-Financial Interests.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1"><p><strong>Publisherâ€™s note</strong> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>
<div class="fn p" id="fn2"><p>These authors contributed equally: Daniel A. Ruiz-Torres, Ross D. Merkin.</p></div>
</div></section><section id="sec15"><h2 class="pmc_sec_title">Supplementary information</h2>
<p>The online version contains supplementary material available at 10.1038/s41698-025-01084-4.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <em>Lancet</em><strong>394</strong>, 1915â€“1928 (2019).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)32591-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31679945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Burtness,%20B.%20et%20al.%20Pembrolizumab%20alone%20or%20with%20chemotherapy%20versus%20cetuximab%20with%20chemotherapy%20for%20recurrent%20or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20(KEYNOTE-048):%20a%20randomised,%20open-label,%20phase%203%20study.%20Lancet394,%201915%E2%80%931928%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Mehra, R. et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <em>Br. J. Cancer</em><strong>119</strong>, 153â€“159 (2018).
</cite> [<a href="https://doi.org/10.1038/s41416-018-0131-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6048158/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29955135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mehra,%20R.%20et%20al.%20Efficacy%20and%20safety%20of%20pembrolizumab%20in%20recurrent/metastatic%20head%20and%20neck%20squamous%20cell%20carcinoma:%20pooled%20analyses%20after%20long-term%20follow-up%20in%20KEYNOTE-012.%20Br.%20J.%20Cancer119,%20153%E2%80%93159%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Harrington, K. J. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. <em>J. Clin. Oncol.</em><strong>41</strong>, 790â€“802 (2023).
</cite> [<a href="https://doi.org/10.1200/JCO.21.02508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9902012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36219809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Harrington,%20K.%20J.%20et%20al.%20Pembrolizumab%20with%20or%20without%20chemotherapy%20in%20recurrent%20or%20metastatic%20head%20and%20neck%20squamous%20cell%20carcinoma:%20updated%20results%20of%20the%20phase%20III%20KEYNOTE-048%20study.%20J.%20Clin.%20Oncol.41,%20790%E2%80%93802%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Cohen, E. E. W. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). <em>J. Immunother. Cancer</em><strong>7</strong>, 184 (2019).
</cite> [<a href="https://doi.org/10.1186/s40425-019-0662-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6632213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31307547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cohen,%20E.%20E.%20W.%20et%20al.%20The%20Society%20for%20Immunotherapy%20of%20Cancer%20consensus%20statement%20on%20immunotherapy%20for%20the%20treatment%20of%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20(HNSCC).%20J.%20Immunother.%20Cancer7,%20184%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Lesterhuis, W. J. et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <em>Nat. Rev. Drug Discov.</em><strong>16</strong>, 264â€“272 (2017).
</cite> [<a href="https://doi.org/10.1038/nrd.2016.233" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28057932/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lesterhuis,%20W.%20J.%20et%20al.%20Dynamic%20versus%20static%20biomarkers%20in%20cancer%20immune%20checkpoint%20blockade:%20unravelling%20complexity.%20Nat.%20Rev.%20Drug%20Discov.16,%20264%E2%80%93272%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Moon, D. H. &amp; Sher, D. J. Oligometastasis in head and neck squamous cell carcinoma. <em>Int. J. Radiat. Oncol.*Biol.*Phys.</em><strong>114</strong>, 803â€“811 (2022).
</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2022.06.086" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35798219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moon,%20D.%20H.%20&amp;%20Sher,%20D.%20J.%20Oligometastasis%20in%20head%20and%20neck%20squamous%20cell%20carcinoma.%20Int.%20J.%20Radiat.%20Oncol.*Biol.*Phys.114,%20803%E2%80%93811%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Sivapalan, L. et al. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. <em>J. Immunother. Cancer</em><strong>11</strong>, e005924 (2023).
</cite> [<a href="https://doi.org/10.1136/jitc-2022-005924" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9853269/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36657818/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sivapalan,%20L.%20et%20al.%20Liquid%20biopsy%20approaches%20to%20capture%20tumor%20evolution%20and%20clinical%20outcomes%20during%20cancer%20immunotherapy.%20J.%20Immunother.%20Cancer11,%20e005924%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Lapin, M. et al. Comprehensive ctDNA measurements improve prediction of clinical outcomes and enable dynamic tracking of disease progression in advanced pancreatic cancer. <em>Clin. Cancer Res.</em><strong>29</strong>, 1267â€“1278 (2023).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-3526" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10068442/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36662807/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lapin,%20M.%20et%20al.%20Comprehensive%20ctDNA%20measurements%20improve%20prediction%20of%20clinical%20outcomes%20and%20enable%20dynamic%20tracking%20of%20disease%20progression%20in%20advanced%20pancreatic%20cancer.%20Clin.%20Cancer%20Res.29,%201267%E2%80%931278%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Thompson, J. C., Scholes, D. G., Carpenter, E. L. &amp; Aggarwal, C. Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors. <em>Br. J. Cancer</em><strong>129</strong>, 1893â€“1902 (2023).
</cite> [<a href="https://doi.org/10.1038/s41416-023-02445-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10703899/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37789101/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Thompson,%20J.%20C.,%20Scholes,%20D.%20G.,%20Carpenter,%20E.%20L.%20&amp;%20Aggarwal,%20C.%20Molecular%20response%20assessment%20using%20circulating%20tumor%20DNA%20(ctDNA)%20in%20advanced%20solid%20tumors.%20Br.%20J.%20Cancer129,%201893%E2%80%931902%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Liu, Z. et al. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer. <em>BMC Med.</em><strong>21</strong>, 493 (2023).
</cite> [<a href="https://doi.org/10.1186/s12916-023-03163-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10717175/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38087296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu,%20Z.%20et%20al.%20Construction%20of%20a%20risk%20stratification%20model%20integrating%20ctDNA%20to%20predict%20response%20and%20survival%20in%20neoadjuvant-treated%20breast%20cancer.%20BMC%20Med.21,%20493%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Taylor, K. et al. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients. <em>Eur. J. Cancer</em><strong>188</strong>, 29â€“38 (2023).
</cite> [<a href="https://doi.org/10.1016/j.ejca.2023.04.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37182343/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Taylor,%20K.%20et%20al.%20Circulating%20tumour%20DNA%20kinetics%20in%20recurrent/metastatic%20head%20and%20neck%20squamous%20cell%20cancer%20patients.%20Eur.%20J.%20Cancer188,%2029%E2%80%9338%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. <em>Cancer Discov.</em><strong>10</strong>, 1842â€“1853 (2020).
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-20-0047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8358981/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32816849/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang,%20Q.%20et%20al.%20Prognostic%20and%20predictive%20impact%20of%20circulating%20tumor%20DNA%20in%20patients%20with%20advanced%20cancers%20treated%20with%20immune%20checkpoint%20blockade.%20Cancer%20Discov.10,%201842%E2%80%931853%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Lee, J. H. et al. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. <em>Clin. Cancer Res.</em><strong>26</strong>, 4064â€“4071 (2020).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-3926" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32321716/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee,%20J.%20H.%20et%20al.%20Longitudinal%20monitoring%20of%20ctDNA%20in%20patients%20with%20melanoma%20and%20brain%20metastases%20treated%20with%20immune%20checkpoint%20inhibitors.%20Clin.%20Cancer%20Res.26,%204064%E2%80%934071%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <em>Nat. Cancer</em><strong>1</strong>, 873â€“881 (2020).
</cite> [<a href="https://doi.org/10.1038/s43018-020-0096-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35121950/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bratman,%20S.%20V.%20et%20al.%20Personalized%20circulating%20tumor%20DNA%20analysis%20as%20a%20predictive%20biomarker%20in%20solid%20tumor%20patients%20treated%20with%20pembrolizumab.%20Nat.%20Cancer1,%20873%E2%80%93881%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Kansara, M. et al. Early circulating tumor &lt;scp&gt;DNA&lt;/scp&gt; dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab. <em>Mol. Oncol.</em><strong>17</strong>, 298â€“311 (2023).
</cite> [<a href="https://doi.org/10.1002/1878-0261.13349" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9892824/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36426653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kansara,%20M.%20et%20al.%20Early%20circulating%20tumor%20&lt;scp&gt;DNA&lt;/scp&gt;%20dynamics%20as%20a%20pan-tumor%20biomarker%20for%20long-term%20clinical%20outcome%20in%20patients%20treated%20with%20durvalumab%20and%20tremelimumab.%20Mol.%20Oncol.17,%20298%E2%80%93311%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Hanna, G. J. et al. Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma. <em>Clin. Cancer Res.</em> OF1â€“OF8 10.1158/1078-0432.CCR-24-0590 (2024).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-24-0590" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11292193/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38824449/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hanna,%20G.%20J.%20et%20al.%20Personalized%20ctDNA%20for%20monitoring%20disease%20status%20in%20head%20and%20neck%20squamous%20cell%20carcinoma.%20Clin.%20Cancer%20Res.%20OF1%E2%80%93OF8%2010.1158/1078-0432.CCR-24-0590%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Ricciuti, B. et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). <em>J. Immunother. Cancer</em><strong>9</strong>, e001504 (2021).
</cite> [<a href="https://doi.org/10.1136/jitc-2020-001504" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7996662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33771889/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ricciuti,%20B.%20et%20al.%20Early%20plasma%20circulating%20tumor%20DNA%20(ctDNA)%20changes%20predict%20response%20to%20first-line%20pembrolizumab-based%20therapy%20in%20non-small%20cell%20lung%20cancer%20(NSCLC).%20J.%20Immunother.%20Cancer9,%20e001504%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Thompson, J. C. et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. <em>JCO Precis. Oncol.</em> 510â€“524 10.1200/PO.20.00321 (2021).</cite> [<a href="https://doi.org/10.1200/PO.20.00321" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8169078/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34095713/" class="usa-link">PubMed</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. <em>Clin. Cancer Res.</em><strong>24</strong>, 1872â€“1880 (2018).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-1341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5899677/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29330207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Goldberg,%20S.%20B.%20et%20al.%20Early%20assessment%20of%20lung%20cancer%20immunotherapy%20response%20via%20circulating%20tumor%20DNA.%20Clin.%20Cancer%20Res.24,%201872%E2%80%931880%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. <em>Nature</em><strong>595</strong>, 432â€“437 (2021).
</cite> [<a href="https://doi.org/10.1038/s41586-021-03642-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34135506/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Powles,%20T.%20et%20al.%20ctDNA%20guiding%20adjuvant%20immunotherapy%20in%20urothelial%20carcinoma.%20Nature595,%20432%E2%80%93437%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Kang, Z., StevanoviÄ‡, S., Hinrichs, C. S. &amp; Cao, L. Circulating cell-free DNA for metastatic cervical cancer detection, genotyping, and monitoring. <em>Clin. Cancer Res.</em><strong>23</strong>, 6856â€“6862 (2017).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-1553" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7885032/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28899967/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kang,%20Z.,%20Stevanovi%C4%87,%20S.,%20Hinrichs,%20C.%20S.%20&amp;%20Cao,%20L.%20Circulating%20cell-free%20DNA%20for%20metastatic%20cervical%20cancer%20detection,%20genotyping,%20and%20monitoring.%20Clin.%20Cancer%20Res.23,%206856%E2%80%936862%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Huffman, B. M. et al. Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders. <em>J. Immunother. Cancer</em><strong>12</strong>, e008436 (2024).
</cite> [<a href="https://doi.org/10.1136/jitc-2023-008436" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10824013/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38272561/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huffman,%20B.%20M.%20et%20al.%20Biomarkers%20of%20pembrolizumab%20efficacy%20in%20advanced%20anal%20squamous%20cell%20carcinoma:%20analysis%20of%20a%20phase%20II%20clinical%20trial%20and%20a%20cohort%20of%20long-term%20responders.%20J.%20Immunother.%20Cancer12,%20e008436%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Gale, D. et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. <em>PLoS ONE</em><strong>13</strong>, e0194630 (2018).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0194630" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5856404/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29547634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gale,%20D.%20et%20al.%20Development%20of%20a%20highly%20sensitive%20liquid%20biopsy%20platform%20to%20detect%20clinically-relevant%20cancer%20mutations%20at%20low%20allele%20fractions%20in%20cell-free%20DNA.%20PLoS%20ONE13,%20e0194630%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Plagnol, V. et al. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. <em>PLoS ONE</em><strong>13</strong>, e0193802 (2018).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0193802" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5854321/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29543828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Plagnol,%20V.%20et%20al.%20Analytical%20validation%20of%20a%20next%20generation%20sequencing%20liquid%20biopsy%20assay%20for%20high%20sensitivity%20broad%20molecular%20profiling.%20PLoS%20ONE13,%20e0193802%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Gouda, M. A. et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). <em>Ann. Oncol.</em><strong>35</strong>, 267â€“275 (2024).
</cite> [<a href="https://doi.org/10.1016/j.annonc.2023.12.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38145866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gouda,%20M.%20A.%20et%20al.%20Liquid%20biopsy%20response%20evaluation%20criteria%20in%20solid%20tumors%20(LB-RECIST).%20Ann.%20Oncol.35,%20267%E2%80%93275%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Gouda, M. A. et al. Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers. <em>JCO Precis. Oncol.</em><strong>6</strong>, e2100512 (2022).
</cite> [<a href="https://doi.org/10.1200/PO.21.00512" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9307306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35834760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gouda,%20M.%20A.%20et%20al.%20Longitudinal%20monitoring%20of%20circulating%20tumor%20DNA%20to%20predict%20treatment%20outcomes%20in%20advanced%20cancers.%20JCO%20Precis.%20Oncol.6,%20e2100512%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Cabel, L. et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. <em>Ann. Oncol.</em><strong>28</strong>, 1996â€“2001 (2017).
</cite> [<a href="https://doi.org/10.1093/annonc/mdx212" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28459943/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cabel,%20L.%20et%20al.%20Circulating%20tumor%20DNA%20changes%20for%20early%20monitoring%20of%20anti-PD1%20immunotherapy:%20a%20proof-of-concept%20study.%20Ann.%20Oncol.28,%201996%E2%80%932001%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Anagnostou, V. et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. <em>Nat. Med.</em><strong>29</strong>, 2559â€“2569 (2023).
</cite> [<a href="https://doi.org/10.1038/s41591-023-02598-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10579094/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37814061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Anagnostou,%20V.%20et%20al.%20ctDNA%20response%20after%20pembrolizumab%20in%20non-small%20cell%20lung%20cancer:%20phase%202%20adaptive%20trial%20results.%20Nat.%20Med.29,%202559%E2%80%932569%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Wyatt, A. W. et al. Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST Working Group. <em>Clin. Cancer Res.</em><strong>30</strong>, 5034â€“5041 (2024).
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-24-1883" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39269996/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wyatt,%20A.%20W.%20et%20al.%20Plasma%20ctDNA%20as%20a%20treatment%20response%20biomarker%20in%20metastatic%20cancers:%20evaluation%20by%20the%20RECIST%20Working%20Group.%20Clin.%20Cancer%20Res.30,%205034%E2%80%935041%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Sanz-Garcia, E. et al. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. <em>Cell Death Differ.</em><strong>31</strong>, 460â€“468 (2024).
</cite> [<a href="https://doi.org/10.1038/s41418-024-01272-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11043441/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38409276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sanz-Garcia,%20E.%20et%20al.%20Multimodal%20detection%20of%20molecular%20residual%20disease%20in%20high-risk%20locally%20advanced%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck.%20Cell%20Death%20Differ.31,%20460%E2%80%93468%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. <em>J. Clin. Oncol.</em><strong>38</strong>, 2830â€“2838 (2020).
</cite> [<a href="https://doi.org/10.1200/JCO.20.00818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7460150/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32484754/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Palma,%20D.%20A.%20et%20al.%20Stereotactic%20ablative%20radiotherapy%20for%20the%20comprehensive%20treatment%20of%20oligometastatic%20cancers:%20long-term%20results%20of%20the%20SABR-COMET%20phase%20II%20randomized%20trial.%20J.%20Clin.%20Oncol.38,%202830%E2%80%932838%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Flach, S. et al. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)â€”a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. <em>Br. J. Cancer</em><strong>126</strong>, 1186â€“1195 (2022).
</cite> [<a href="https://doi.org/10.1038/s41416-022-01716-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9023460/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35132238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Flach,%20S.%20et%20al.%20Liquid%20BIOpsy%20for%20MiNimal%20RESidual%20DiSease%20Detection%20in%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma%20(LIONESS)%E2%80%94a%20personalised%20circulating%20tumour%20DNA%20analysis%20in%20head%20and%20neck%20squamous%20cell%20carcinoma.%20Br.%20J.%20Cancer126,%201186%E2%80%931195%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12373877/bin/41698_2025_1084_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Supp.Material_Merged_revised_V4</a><sup> (956.1KB, pdf) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data is provided within the manuscript or supplementary information files. The code used in this manuscript is publicly available: <a href="https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git</a>.</p>
<p>The underlying code used for this study is publicly available: <a href="https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://github.com/druiztorre/ctDNA_HNSCC_ICB_NPJ.git</a>.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from NPJ Precision Oncology are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41698-025-01084-4"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41698_2025_Article_1084.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.1Â MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12373877/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12373877/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12373877%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373877/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12373877/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12373877/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40846896/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12373877/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40846896/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12373877/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12373877/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="i8025hUxzzBRPKONJXv1PEZ5bUCORP7E2K2dQ5ultwT2Knp7FesThkffZqQCX1Fe">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
